TABLE 1.

Estimated parameter values from the URSA model of Greco et al. in ADAPT 5 for each strain/phenotype^a

Parameter (drug)	Replicate	Unit	Value (95% CI) for the following strain, phenotype:
			H37RV, log phase	H37RV acid phase	18b NRP
ECON	1	log10 (CFU/ml)	7.63 (6.70–8.55)b	6.20 (5.96–6.44)	4.35 (4.05–4.66)
	2	log10 (CFU/ml)	7.03 (6.16–7.89)b	5.84 (5.66–6.02)	4.44 (4.13–4.74)
IC50,1 (PA824)	1	mg/liter	0.0714 (0.046–0.0968)c	0.108 (0.0987–0.118)d	0.445 (0.355–0.534)
	2	mg/liter	0.0649 (0.0493–0.0805)c	0.129 (0.122–0.136)d	0.409 (0.307–0.51)
IC50,2 (MXF)	1	mg/liter	0.0640 (0.0571–0.0708)e	0.0881 (0.0818–0.0945)d ,f	0.514 (0.389–0.639)
	2	mg/liter	0.0662 (0.0559–0.0766)e	0.121 (0.111–0.130)d	0.602 (0.449–0.755)
m1 (PA824)	1		1.57 (0.966–2.17)d	5.55 (3.00–8.1)	2.37 (1.49–3.25)
	2		4.19 (0.649–7.74)	5.56 (2.46–8.66)	1.70 (1.15–2.26)
m2 (MXF)	1		25.08 (−16.8–67.0)	4.35 (3.62–5.08)	1.41 (1.05–1.77)
	2		14.2 (−6.61–35)	37.2 (−50–124.4)	1.46 (1.07–1.85)

^aCI, 95% confidence interval; IC_50,1 and IC_50,2, concentration for half-maximal effect for PA824 and MXF, respectively; m₁ and m₂, Hill constants for PA824 and MXF, respectively; E_CON, effect for the control.

^bP < 0.05 between the H37Rv strain at log phase, the H37Rv strain at acid phase, and the 18b strain at NRP phase.

^cP < 0.05 between the H37Rv strain at log phase, the H37Rv strain at acid phase, and the 18b strain at NRP phase for PA824.

^dP < 0.05 between the H37Rv strain at acid phase and the 18b strain at NRP phase for PA824.

^eP < 0.05 between the H37Rv strain at log phase, the H37Rv strain at acid phase, and the 18b strain at NRP phase for MXF.

^fP < 0.05 between IC_50,1 (PA824) and IC_50,2 (MXF).